Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2025)

Xeris Biopharma Holdings' Gains from Investment Securities history spans 6 years, with the latest figure at $1.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 827.71% year-over-year to $1.5 million, compared with a TTM value of $10.9 million through Dec 2025, up 191.27%, and an annual FY2025 reading of $10.9 million, up 191.27% over the prior year.
  • Gains from Investment Securities for Q4 2025 was $1.5 million at Xeris Biopharma Holdings, up from $478000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $20.0 million in Q2 2023, with the low at -$236000.0 in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $2.3 million, with a median of $447000.0 recorded in 2022.
  • Biggest YoY gain for Gains from Investment Securities was 53500.0% in 2021; the steepest drop was 150.62% in 2021.
  • Tracing XERS's Gains from Investment Securities over 5 years: stood at $534000.0 in 2021, then plummeted by 144.19% to -$236000.0 in 2022, then surged by 120.76% to $49000.0 in 2023, then soared by 238.78% to $166000.0 in 2024, then surged by 827.71% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Gains from Investment Securities are $1.5 million (Q4 2025), $478000.0 (Q3 2025), and $860000.0 (Q2 2025).